Morgan Stanley downgrade on semaglutide patent cliff sinks Novo Nordisk
The bank flags the approaching loss of exclusivity for Novo's lead incretin franchise as the driver of the rating cut.
TR
By Tom Reyes · Markets Editor
Sep 11 03:00 ETSource: Yahoo Finance
The wire
- 01Novo Nordisk shares fell after a Morgan Stanley downgrade centred on the coming semaglutide patent cliff, according to the report.
- 02Semaglutide exclusivity timing shapes pricing, supply and eventual generic entry that compounders, payers and telehealth operators plan around.
- 03Analyst calls are not company events; details of the timing and Novo's response are not laid out in the item.
From the source
Read at finance.yahoo.comNovo Nordisk Stock Plunges on Morgan Stanley Downgrade Warns of Semaglutide Patent Cliff